TABLE 5.

Demographics and clinical outcomes of clinical pregnancy

	Increasing dose		Constant dose		P value
	Primipara	Multipara	Primipara	Multipara
n	58	29	57	30
Female age (years)	34.2 ± 5.3	36.2 ± 3.4	34.2 ± 5.3	35.0 ± 3.9	.246 a
Recurrent pregnancy loss	4 (6.9)	4 (13.8)	2 (3.5)	1 (3.3)	.305 b
Body mass index (kg/m2)	20.7 ± 2.3	20.3 ± 2.6	21.1 ± 2.9	21.4 ± 3.1	.275 a
Recurrent pregnancy loss	4 (6.9)	4 (13.8)	2 (3.5)	1 (3.3)	.305 b
Serum AMH (ng/mL)	4.7 ± 18.5	4.4 ± 14.2	3.9 ± 7.2	3.4 ± 3.5	.822 a
No. of previous ET cycles	2.1 ± 5.2	0.8 ± 1.7	2.1 ± 5.5	1.3 ± 1.8	.003 a
Serum estradiol (pg/mL)
On the 14th day of ERT	454 ± 265	440 ± 247	279 ± 168	243 ± 124	<.001 a
On the day of FET	278 ± 143	281 ± 128	267 ± 157	255 ± 188	.276 a
Endometrial thickness (mm)
On the 14th day of ERT	10.4 ± 2.2	10.8 ± 2.2	10.8 ± 2.7	10.2 ± 1.9	.745 a
On the day of FET	10.3 ± 2.1	10.1 ± 2.3	10.7 ± 2.7	10.8 ± 2.0	.275 a

Data are expressed as mean ± standard deviation or number (%).

Abbreviations: AMH, anti‐Müllerrian hormone; ERT, estrogen replacement therapy; ET, embryo transfer; FET, frozen‐thawed embryo transfer.

^aKruskal‐Wallis test.

^bFisher's exact test.